Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cement could help teeth heal themselves

NCT ID NCT07507136

Disease control Sponsor: Albos d.o.o. Beograd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested a new dental cement called ALBO-MPCA in 20 adults with tooth decay. The cement is designed to stimulate the tooth to grow new dentin, the hard layer under the enamel. The goal was to see if it is safe and effective for repairing cavities and protecting the tooth nerve.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ALBO-MPCA (a calcium-silicate dental cement)
What this could lead to
If successful, this cement could offer a better way to repair tooth decay by helping teeth grow new dentin, potentially reducing the need for more invasive treatments.
What could go wrong
This is a very small, early-phase trial with only 20 people, so results may not apply to everyone. The cement is new and long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Apr 2023

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent has been signed * Age 18 years and above * Carious teeth that had no previous treatment * Pulpal diagnosis of normal, healthy pulp * Symptomless, curiously exposed vital teeth * No clinical symptoms or evidence of pulp degeneration, such as history of spontaneous pain and tenderness to percussion, history of swelling or sinus tracts, pathologic mobility * Teeth are restorable * No radiographic evidence of pulp degeneration, such as internal or external resorption, inter-radicular, and/or periapical bone destruction, or pulp stones * No clinical evidence of pulp degeneration, such as excessive bleeding from the pulp Exclusion Criteria: * Pregnancy and lactation 6 months before the study and during the study * Significant renal or hepatic impairment * Subject with a life expectancy of less than 6 months * Subjects with unacceptable occlusal interferences oral hygiene, and non-compliant patients * History of irreversible pulpal pain * Immature teeth * Non-restorable teeth * Teeth with active periodontal disease * History of any systemic disease * Concurrent medication with systemic steroids, antibiotics, analgetics, immunomodulatory drugs, or cytostatics * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial * Participation in another research trial involving an investigational product in the past 12 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dental caries are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dental caries

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dental caries

Contacts and locations

Locations

  • Health House Foča

    Foca, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.